KR102673794B1 - 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 - Google Patents
나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 Download PDFInfo
- Publication number
- KR102673794B1 KR102673794B1 KR1020207001253A KR20207001253A KR102673794B1 KR 102673794 B1 KR102673794 B1 KR 102673794B1 KR 1020207001253 A KR1020207001253 A KR 1020207001253A KR 20207001253 A KR20207001253 A KR 20207001253A KR 102673794 B1 KR102673794 B1 KR 102673794B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- composition
- nlc
- lipid
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020247018651A KR20240096685A (ko) | 2017-06-15 | 2018-06-15 | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762520204P | 2017-06-15 | 2017-06-15 | |
| US62/520,204 | 2017-06-15 | ||
| US201762540973P | 2017-08-03 | 2017-08-03 | |
| US62/540,973 | 2017-08-03 | ||
| US201762556291P | 2017-09-08 | 2017-09-08 | |
| US62/556,291 | 2017-09-08 | ||
| US201762563544P | 2017-09-26 | 2017-09-26 | |
| US62/563,544 | 2017-09-26 | ||
| US201762582859P | 2017-11-07 | 2017-11-07 | |
| US62/582,859 | 2017-11-07 | ||
| US201862622748P | 2018-01-26 | 2018-01-26 | |
| US201862622755P | 2018-01-26 | 2018-01-26 | |
| US62/622,748 | 2018-01-26 | ||
| US62/622,755 | 2018-01-26 | ||
| US201862669262P | 2018-05-09 | 2018-05-09 | |
| US62/669,262 | 2018-05-09 | ||
| US201862677336P | 2018-05-29 | 2018-05-29 | |
| US62/677,336 | 2018-05-29 | ||
| US201862680454P | 2018-06-04 | 2018-06-04 | |
| US62/680,454 | 2018-06-04 | ||
| PCT/US2018/037783 WO2018232257A1 (en) | 2017-06-15 | 2018-06-15 | Nanostructured lipid carriers and stable emulsions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247018651A Division KR20240096685A (ko) | 2017-06-15 | 2018-06-15 | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200028395A KR20200028395A (ko) | 2020-03-16 |
| KR102673794B1 true KR102673794B1 (ko) | 2024-06-11 |
Family
ID=62948328
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207001253A Active KR102673794B1 (ko) | 2017-06-15 | 2018-06-15 | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
| KR1020247018651A Ceased KR20240096685A (ko) | 2017-06-15 | 2018-06-15 | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247018651A Ceased KR20240096685A (ko) | 2017-06-15 | 2018-06-15 | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11141377B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3638207B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7866358B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102673794B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111315362A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018285694B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019026615B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3067224A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3003260T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL271384B2 (cg-RX-API-DMAC7.html) |
| MX (4) | MX2019015076A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018232257A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201908207B (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018285694B2 (en) | 2017-06-15 | 2025-04-10 | Access To Advanced Health Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
| US12180370B2 (en) | 2019-01-15 | 2024-12-31 | Nant Holdings Ip, Llc | Aragonite uses |
| US12514796B2 (en) | 2019-01-15 | 2026-01-06 | Nant Holdings Ip, Llc | Aragonite compositions, methods, and uses thereof |
| US20220339116A1 (en) * | 2019-04-03 | 2022-10-27 | The Johns Hopkins University | Lipid nanoparticles as oral vehicles of immunotherapy |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| WO2021194672A1 (en) | 2020-03-23 | 2021-09-30 | Hdt Bio Corp. | Compositions and methods for delivery of rna |
| EP4058581A1 (en) * | 2019-11-15 | 2022-09-21 | Infectious Disease Research Institute | Rig-i agonist and adjuvant formulation for tumor treatment |
| AU2021226149A1 (en) * | 2020-02-26 | 2022-10-06 | Capcium Inc. | Nanostructure lipid carrier delivery system, composition, and methods |
| CN111494619B (zh) * | 2020-04-26 | 2022-03-18 | 南京农业大学 | 一种基于角鲨烯的阳离子纳米结构脂质载体免疫佐剂的制备方法 |
| US20230310323A1 (en) | 2020-09-04 | 2023-10-05 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
| WO2022051024A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Genetically-adjuvanted rna vaccines |
| JP2024501949A (ja) * | 2020-12-23 | 2024-01-17 | アクセス ツー アドバンスト ヘルス インスティチュート | ソラネソールワクチンアジュバント及びその調製方法 |
| US20240252620A1 (en) * | 2021-05-28 | 2024-08-01 | The Regents Of The University Of Michigan | Combined agonist adjuvant for coronavirus vaccine |
| IN202121031414A (cg-RX-API-DMAC7.html) * | 2021-07-13 | 2023-01-13 | ||
| US20240327492A1 (en) | 2021-07-29 | 2024-10-03 | Nantcell, Inc. | Modified T Cell Receptors For The Prevention And Treatment Of Viral Infections And Cancer |
| KR102681030B1 (ko) * | 2021-08-02 | 2024-07-02 | 한국화학연구원 | 올리고뉴클레오타이드가 봉입된 나노입자, 이의 제조방법 및 이를 포함하는 약학적 제제 |
| US20250134991A1 (en) * | 2021-08-20 | 2025-05-01 | Thomas Jefferson University | Monophosphoryl lipid adjuvant (mpla) compositions, vaccine compositions thereof, and methods of preparing and using the same |
| AU2022352486A1 (en) * | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Dried nanoparticle compositions |
| JP2024535352A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | Sars-cov-2 rnaワクチン組成物および使用方法 |
| CA3232658A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Rna vaccines against infectious diseases |
| CA3232562A1 (en) * | 2021-09-22 | 2023-03-30 | Malcolm S. Duthie | Nucleic acid sensor agonist compositions and uses thereof |
| AU2022358446A1 (en) * | 2021-09-22 | 2024-04-18 | Hdt Bio Corp. | Compositions and methods for enhanced protein production |
| WO2023049636A2 (en) * | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Cancer therapy compositions and uses thereof |
| EP4460326A4 (en) * | 2022-01-07 | 2026-03-11 | Hdt Bio Corp | COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIVALENT IMMUNE RESPONSES |
| WO2023228116A1 (en) | 2022-05-24 | 2023-11-30 | Access To Advanced Health Institute | Intranasal administration of thermostable rna vaccines |
| EP4547258A4 (en) * | 2022-06-28 | 2026-08-05 | Transcode Therapeutics Inc | Matrix-Directed Rig-I Agonitor Nanoparticles and Precursor Compositions and Their Uses in Cancer Therapy |
| KR102901149B1 (ko) * | 2022-09-05 | 2025-12-17 | 주식회사 차백신연구소 | 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법 |
| WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
| CN116159145B (zh) * | 2023-01-31 | 2025-04-22 | 四川大学 | 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用 |
| CN116392586B (zh) * | 2023-04-12 | 2025-06-24 | 江苏中慧元通生物科技股份有限公司 | 一种纳米乳佐剂 |
| EP4694920A1 (en) * | 2023-04-14 | 2026-02-18 | BioNTech SE | Rna for preventing or treating tuberculosis |
| EP4734962A1 (en) * | 2023-06-29 | 2026-05-06 | RIGImmune Inc. | Novel formulations |
| WO2025244961A1 (en) * | 2024-05-22 | 2025-11-27 | Merck Sharp & Dohme Llc | Processes for making stable nanoemulsion adjuvants |
| WO2026096272A1 (en) * | 2024-10-30 | 2026-05-07 | Virginia Commonwealth University | Equine lyme disease vaccines and methods |
| ES3069647A1 (es) * | 2024-12-09 | 2026-06-09 | Consejo Superior Investigacion | Transportadores lipídicos nanoestructurados para inhibir la formación de biopelículas bacterianas |
| CN121944103B (zh) * | 2026-04-03 | 2026-07-03 | 华诺泰生物医药科技(成都)有限公司 | 一种含角鲨烯的水包油佐剂及其制备方法与应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120156251A1 (en) * | 2010-07-06 | 2012-06-21 | Luis Brito | Cationic oil-in-water emulsions |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| EP0304578B1 (en) | 1987-06-22 | 2001-10-24 | Medeva Holdings Bv | Peptide comprising hepatitis B surface antigen |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
| US4999403A (en) | 1988-10-28 | 1991-03-12 | Exxon Chemical Patents Inc. | Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions |
| JP3237842B2 (ja) | 1988-12-16 | 2001-12-10 | オランダ国 | ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン |
| ATE115862T1 (de) | 1989-02-04 | 1995-01-15 | Akzo Nobel Nv | Tocole als impfstoffadjuvans. |
| DK0414374T3 (da) | 1989-07-25 | 1998-03-09 | Smithkline Beecham Biolog | Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf |
| US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
| EP1359156B1 (en) | 1991-07-19 | 2007-03-07 | University of Queensland | Vaccine against Human Papillomavirus (Type 18) |
| JP3954643B2 (ja) | 1991-11-16 | 2007-08-08 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | マラリア原虫由来のCSおよびHBsAG間のハイブリッド蛋白質 |
| PT647140E (pt) | 1992-06-25 | 2007-12-27 | Univ Georgetown | Vacinas de papilomavírus |
| US5786148A (en) | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
| US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| DE69434383T2 (de) | 1993-03-09 | 2005-11-24 | The University Of Rochester | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| EP1728800A1 (de) | 1994-10-07 | 2006-12-06 | Loyola University Of Chicago | Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung |
| AU4727296A (en) | 1995-02-24 | 1996-09-11 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
| US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
| US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| ES2301178T3 (es) | 1996-04-05 | 2008-06-16 | Novartis Vaccines & Diagnostic | Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular. |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US5955306A (en) | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
| US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
| CA2281954A1 (en) | 1997-02-25 | 1998-08-27 | Corixa Corporation | Compounds for immunodiagnosis of prostate cancer and methods for their use |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| AU740956B2 (en) | 1997-07-21 | 2001-11-15 | Baxter Healthcare Sa | Modified immunogenic pneumolysin compositions as vaccines |
| GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
| KR100760221B1 (ko) | 1997-11-28 | 2007-10-30 | 세로노 제네틱스 인스티튜트 에스.에이. | 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도 |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| BR9907691B1 (pt) | 1998-02-05 | 2011-05-31 | derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina. | |
| BR9909472A (pt) | 1998-04-07 | 2001-09-11 | Corixa Corp | Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica |
| JP2002511266A (ja) | 1998-04-15 | 2002-04-16 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 腫瘍関連核酸及びその使用 |
| TR200100916T2 (cg-RX-API-DMAC7.html) | 1998-07-14 | 2002-06-21 | Corixa@@Corporation | |
| DK1187629T3 (da) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
| US6533949B1 (en) | 2000-08-28 | 2003-03-18 | Nanopass Ltd. | Microneedle structure and production method therefor |
| US20030138453A1 (en) | 2000-09-28 | 2003-07-24 | O'hagan Derek | Microparticles for delivery of heterologous nucleic acids |
| WO2004058166A2 (en) | 2002-12-23 | 2004-07-15 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| US7998119B2 (en) | 2003-11-18 | 2011-08-16 | Nano Pass Technologies Ltd. | System and method for delivering fluid into flexible biological barrier |
| JP5331340B2 (ja) | 2004-05-18 | 2013-10-30 | バイカル インコーポレイテッド | インフルエンザウィルスワクチン組成物、及びその使用方法 |
| EP2468300B1 (en) | 2006-09-26 | 2017-12-20 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| WO2008124647A2 (en) | 2007-04-04 | 2008-10-16 | Infectious Disease Research Institute | Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof |
| EP2200639B1 (en) * | 2007-09-24 | 2016-03-30 | Government of the USA, as Represented by the Secretary, Department of Health and Human Services | Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
| US9636410B2 (en) | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| RU2014104090A (ru) * | 2011-07-06 | 2015-08-20 | Новартис Аг | Липосомы с эффективным соотношением n:p для доставки молекул phk |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| US10322089B2 (en) * | 2012-03-14 | 2019-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Nanoparticles, nanoparticle delivery methods, and systems of delivery |
| US8809388B2 (en) * | 2012-11-06 | 2014-08-19 | Brandeis University | Vegetable oil composition containing palm mid-fraction fat and method of reducing plasma cholesterol |
| AU2014204826A1 (en) * | 2013-01-10 | 2015-07-09 | Seqirus UK Limited | Influenza virus immunogenic compositions and uses thereof |
| CN115837014A (zh) * | 2016-05-18 | 2023-03-24 | 摩登纳特斯有限公司 | 编码松弛素的多核苷酸 |
| AU2018285694B2 (en) | 2017-06-15 | 2025-04-10 | Access To Advanced Health Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
-
2018
- 2018-06-15 AU AU2018285694A patent/AU2018285694B2/en active Active
- 2018-06-15 MX MX2019015076A patent/MX2019015076A/es unknown
- 2018-06-15 CN CN201880050697.XA patent/CN111315362A/zh active Pending
- 2018-06-15 KR KR1020207001253A patent/KR102673794B1/ko active Active
- 2018-06-15 IL IL271384A patent/IL271384B2/en unknown
- 2018-06-15 CA CA3067224A patent/CA3067224A1/en active Pending
- 2018-06-15 KR KR1020247018651A patent/KR20240096685A/ko not_active Ceased
- 2018-06-15 WO PCT/US2018/037783 patent/WO2018232257A1/en not_active Ceased
- 2018-06-15 US US16/622,908 patent/US11141377B2/en active Active
- 2018-06-15 BR BR112019026615-1A patent/BR112019026615B1/pt active IP Right Grant
- 2018-06-15 EP EP18742621.8A patent/EP3638207B1/en active Active
- 2018-06-15 ES ES18742621T patent/ES3003260T3/es active Active
- 2018-06-15 JP JP2019569758A patent/JP7866358B2/ja active Active
-
2019
- 2019-12-10 ZA ZA2019/08207A patent/ZA201908207B/en unknown
- 2019-12-13 MX MX2023006661A patent/MX2023006661A/es unknown
- 2019-12-13 MX MX2022013322A patent/MX2022013322A/es unknown
- 2019-12-13 MX MX2022013320A patent/MX2022013320A/es unknown
-
2021
- 2021-09-09 US US17/470,874 patent/US12201722B2/en active Active
-
2024
- 2024-01-04 JP JP2024000126A patent/JP2024029173A/ja not_active Withdrawn
- 2024-12-11 US US18/977,878 patent/US20250241854A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120156251A1 (en) * | 2010-07-06 | 2012-06-21 | Luis Brito | Cationic oil-in-water emulsions |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12201722B2 (en) | Nanostructured lipid carriers and stable emulsions and uses thereof | |
| US20230310323A1 (en) | Co-lyophilized rna and nanostructured lipid carrier | |
| JP6025721B2 (ja) | カチオン性水中油型エマルジョン | |
| JP6120839B2 (ja) | カチオン性水中油型エマルジョン | |
| JP2015522580A (ja) | 免疫学的組成物およびその使用 | |
| JP2017057213A (ja) | 核酸を含む水中油型エマルジョン | |
| US20230310569A1 (en) | Genetically-adjuvanted rna vaccines | |
| Adamiak et al. | Archaeosomes and gas vesicles as tools for vaccine development | |
| CN121548645A (zh) | 用于稳定rna的方法 | |
| Gholami et al. | Delivery systems for Leishmania vaccine development | |
| WO2024052882A1 (en) | Immunogenic vaccine composition incorporating a saponin | |
| RU2816240C2 (ru) | Наноструктурированные липидные носители и стабильные эмульсии и их применения | |
| HK40028242A (en) | Nanostructured lipid carriers and stable emulsions and uses thereof | |
| US20250295744A1 (en) | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200114 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210611 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230801 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240318 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240604 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240605 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |